So, I’ve been with the company a little over a year. We are focused very much on these strategic growth initiatives, driving our EP adoption, launching our vascular business and achieving operating excellence in all that we do. We’ll talk more about these later in the slides. But relative to driving our EP adoption, we are – have launched new products but we’ll be launching new products going forward. We continue to invest heavily in clinical data and the publication of that data when it comes out.We’ve done a significant upgrade of our commercial team especially in the US, we’ve hired and have established in my opinion one of the best training centers for a company anywhere. And it really I think goes to a lot of success we’ve seen in EP and we’ll see in the vascular space. On the vascular side, again, it’s all about Magellan and we’ll go into detail on that and lastly, operational excellence.
Hansen Medical's CEO Presents At JP Morgan Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.